Menopausal Hormone Therapy Shows No Long-Term Cognitive Effects in Early Postmenopausal Women

**New research published in PLOS Medicine reveals that short-term menopausal hormone therapy (MHT), when administered to women in early postmenopause, has no long-term cognitive effects**. The study, led by Carey Gleason from the University of Wisconsin-Madison, may offer reassurance to those hesitant about MHT due to safety concerns. Previous studies had linked one form of hormone therapy to mild cognitive impairment and dementia in women over 65, sparking interest in how age and timing affect cognitive outcomes. The **Kronos Early Estrogen Prevention Study (KEEPS)** investigated women with good cardiovascular health, comparing oral or transdermal estrogen against placebo over four years. It was found that there was neither cognitive harm nor benefit from MHT. A decade later, the follow-up **KEEPS Continuation Study** revisited 275 participants, confirming no long-term cognitive decline associated with MHT. Although results are promising, highlighting the importance of timing in MHT, they are yet to be generalized to women with higher cardiovascular risk. The authors emphasize the need for clear, evidence-based information to guide healthcare decisions regarding MHT.